TY - JOUR
T1 - Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant
AU - Heslop, Helen
AU - Perez, Margot
AU - Benaim, Ely
AU - Rochester, Richard
AU - Brenner, Malcolm
AU - Rooney, Cliona M.
PY - 1999/11/22
Y1 - 1999/11/22
N2 - EBV-associated lymphoproliferative disorders (EBV-LPD) are a significant problem after hemopoietic stem cell transplantation from unrelated donors or mismatched family members. Risk factors include T-cell depletion, MHC mismatch, and intensity of immunosuppression. New therapeutic strategies involve cellular immunotherapy approaches and both donor T-cells and EBV- specific cytotoxic T lymphocytes (CTLs) have proven to be effective therapies. EBV-specific CTL has also proved to have a major impact on the incidence of this complication when used prophylactically.
AB - EBV-associated lymphoproliferative disorders (EBV-LPD) are a significant problem after hemopoietic stem cell transplantation from unrelated donors or mismatched family members. Risk factors include T-cell depletion, MHC mismatch, and intensity of immunosuppression. New therapeutic strategies involve cellular immunotherapy approaches and both donor T-cells and EBV- specific cytotoxic T lymphocytes (CTLs) have proven to be effective therapies. EBV-specific CTL has also proved to have a major impact on the incidence of this complication when used prophylactically.
UR - http://www.scopus.com/inward/record.url?scp=0032708999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032708999&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1098-1101(1999)14:3<154::AID-JCA9>3.0.CO;2-K
DO - 10.1002/(SICI)1098-1101(1999)14:3<154::AID-JCA9>3.0.CO;2-K
M3 - Review article
C2 - 10540372
AN - SCOPUS:0032708999
SN - 0733-2459
VL - 14
SP - 154
EP - 156
JO - Journal of Clinical Apheresis
JF - Journal of Clinical Apheresis
IS - 3
ER -